Abstract | Introduction: Material and methods: MEDLINE, Embase, The Cochrane Library, and Clinical Trials databases were electronically searched from inception to January 2019. Two reviewers independently screened literature and extracted data, and then R and RevMan 5.3 software packages were used to perform network meta-analysis. Results: The relative risk of respiratory distress syndrome in preterm infants associated with six different pulmonary surfactant was analysed, including beractant ( Survanta), surfactant A ( Alveofact), calfactant ( Infasurf), poractant ( Curosurf), lucinactant (Surfaxin), and colfosceril ( Exosurf). Patients with the following drugs appeared to have significantly reduced mortality of respiratory distress syndrome compare with beractant: surfactant A (OR = 0.53, 95% CI: 0.31-0.90), calfactant (OR = 0.91, 95% CI: 0.85-0.97), poractant (OR = 0.72, 95% CI: 0.67-0.77), lucinactant (OR = 0.80, 95% CI: 0.71-0.90), and colfosceril (OR = 0.93, 95% CI: 0.87-0.99). The SUCRA (surface under the cumulative ranking) values for each of the drugs were: beractant (8.9%), surfactant A (93.8%), calfactant (40.3%), poractant (65.4%), lucinactant (59.8%), and colfosceril (31.6%). Conclusions:
|
Authors | Caihong Qiu, Cui Ma, Nana Fan, Xiaoyu Zhang, Guofeng Zheng |
Journal | Archives of medical science : AMS
(Arch Med Sci)
Vol. 19
Issue 5
Pg. 1446-1453
( 2023)
ISSN: 1734-1922 [Print] Poland |
PMID | 37732036
(Publication Type: Journal Article, Review)
|
Copyright | Copyright: © 2020 Termedia & Banach. |